Ishara Investments LP Invests $1.01 Million in Lexicon Pharmaceuticals, Inc. $LXRX

Ishara Investments LP acquired a new position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 880,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,012,000. Lexicon Pharmaceuticals accounts for approximately 1.2% of Ishara Investments LP’s investment portfolio, making the stock its 29th biggest position.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Security National Bank of Sioux City Iowa IA purchased a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter worth $31,000. Hudson Bay Capital Management LP purchased a new position in Lexicon Pharmaceuticals during the second quarter valued at $26,000. Leonteq Securities AG purchased a new position in Lexicon Pharmaceuticals during the fourth quarter valued at $34,000. Vermillion & White Wealth Management Group LLC grew its stake in Lexicon Pharmaceuticals by 400.0% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 26,000 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new position in Lexicon Pharmaceuticals during the fourth quarter valued at $39,000. 74.70% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Stock Performance

LXRX opened at $2.04 on Thursday. The stock has a market capitalization of $906.16 million, a price-to-earnings ratio of -29.14 and a beta of 1.07. The company has a fifty day moving average of $1.93 and a 200 day moving average of $1.59. Lexicon Pharmaceuticals, Inc. has a fifty-two week low of $0.70 and a fifty-two week high of $2.53. The company has a debt-to-equity ratio of 0.24, a quick ratio of 18.77 and a current ratio of 18.80.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $0.00 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.04. Lexicon Pharmaceuticals had a negative net margin of 37.46% and a negative return on equity of 18.64%. The business had revenue of $21.10 million during the quarter, compared to analyst estimates of $9.79 million. As a group, sell-side analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Lexicon Pharmaceuticals in a research note on Monday, March 23rd. Citigroup raised their target price on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the company a “buy” rating in a research note on Monday, May 11th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Lexicon Pharmaceuticals has an average rating of “Hold” and an average price target of $4.55.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.